Klebsiella pneumoniae is a rod shaped type of bacteria commonly found in the normal flora of the mouth, skin, and intestines.
K. pneumoniae can in turn cause an infection called klebsiella pneumonia. This can provoke lung inflammation and cell death that may produce a thick, bloody, mucoid sputum. This often happens after the bacteria migrate from their normal place of resting to the lower respiratory tract. (For more on this see the questions below)
The KPC superbug arises when the Klebsiella bacteria become resistant to the carbapenem drugs often used to treat them. These drug resistant bacteria are called Carbapenemases. They are active in other bacteria beside Klebsiella and this resistance group are sometimes referred to as Carbapenem Resistant En (CRE)
Different types of KPC exist around the world and are most often seen in hospital patients with compromised immune systems and significant exposure to hospital infections. They have spread around the USA in the last 10 years and often have a foothold in long term care facilities.
They have gained media attention since September 2012 because of the interest in the battle that the National Insitute of Health experienced in uprooting the infection from their state of the art facility and the many deaths that have occurred from one single outbreak. KPC and CRE are considered to be among the most potent threats to public health in the world at this time. They threaten to turn formerly treatable infections into life ending challenges.
See our KPC superbug guide below
- KPC News – Daily Updates
- How is the KPC superbug treated
- What are KPC superbug symptoms
- What is Klebsiella Pneumonia?
- What is the KPC superbug?
The latest news on carbapenemases is below. You can sign up for our weekday newsletter here
- A. baumannii , P. aeruginosa outnumber CRE in US hospitals
- ASK2 Bioactive Compound Inhibits MDR Klebsiella pneumoniae by Antibiofilm Activity, Modulating Macrophage Cytokines and Opsonophagocytosis.
- Synergistic activity of fosfomycin, β-lactams and peptidoglycan recycling inhibition against Pseudomonas aeruginosa.
- Phenotypic detection of the cfiA metallo-β-lactamase in Bacteroides fragilis with the meropenem-EDTA double-ended Etest and the ROSCO KPC/MBL Confirm Kit.
- Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.
- Antimicrobial susceptibility patterns of clinical isolates of Pseudomonas aeruginosa isolated from patients of respiratory tract infections in a Tertiary Care Hospital, Peshawar.
- Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery.
- [Distribution and drug resistance of pathogens at hematology department of Jiangsu Province from 2014 to 2015: results from a multicenter, retrospective study].
- IncX3 plasmid harboring a non-Tn4401 genetic element (NTEKPC) in a hospital-associated clone of KPC-2-producing Klebsiella pneumoniae ST340/CG258.
- Activity of the β-Lactamase inhibitor LN-1-255 against carbapenem-hydrolyzing class D β-lactamases from Acinetobacter baumannii.
- Correction: EUropean prospective cohort study on Enterobacteriaceae showing REsistance to CArbapenems (EURECA): a protocol of a European multicentre observational study.
- Clinical Microbiology Market Is Driven By Rising Occurrence 2025 - Medgadget (blog)
- Rectal swab screening assays of public health importance in molecular diagnostics: Sample adequacy control.
- Cluster of Carbapenemase-Producing Enterobacteriaceae cases in Kowloon Hospital - 7thSpace Interactive (press release)
- Should you finish the course of antibiotics? Yes—(until further notice) | Center for Disease Dynamics, Economics & Policy (CDDEP)